Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM)

Rossella E. Nappi, Erica Terreno, Grazia Sances, Ellis Martini, Silvia Tonani, Valentina Santamaria, Cristina Tassorelli, Arsenio Spinillo

Research output: Contribution to journalArticlepeer-review

Abstract

Background Combined hormonal contraception might worsen migraine in sensitive women, especially during the free-hormone interval, and raise concerns about the vascular risk. The characteristics of a contraceptive pill containing estradiol valerate/dienogest (E2V/DNG) might be of potential benefit in women with menstrually related migraine (MRM) who choose to use oral contraception for birth control. Study design This was a prospective diary-based pilot study. Thirty-two women (age > 35 years) [n= 18 who had never used combined oral contraceptives (COCs) and n= 14 who had previously used COCs] diagnosed with MRMs according to the International Headache Society criteria were included. During the observational period, women filled in a diary with the clinical characteristics of migraine attacks. After a three-cycle run-in period, each subject received a COC containing E2V/DNG (Qlaira®/Natazia®; Bayer HealthCare, Berlin, Germany) administered using an estrogen step-down and progestogen step-up approach. Follow-up evaluations were scheduled at the last cycle of run-in and at the third and sixth cycles of treatment. Results The number of migraine attacks was significantly reduced at the third (p

Original languageEnglish
Pages (from-to)369-375
Number of pages7
JournalContraception
Volume88
Issue number3
DOIs
Publication statusPublished - Sep 2013

Keywords

  • Bleeding
  • Dienogest
  • Dysmenorrhea
  • Estradiol valerate
  • Hormonally associated headaches
  • Migraine without aura

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM)'. Together they form a unique fingerprint.

Cite this